Christopher Hite, serving as the Executive Vice President and Chairman of Partnering at Royalty Pharma plc (NASDAQ:RPRX), completed a significant divestment of company stock on June 23, 2026. The transaction involved the sale of 150,000 Class A Ordinary Shares, generating proceeds of $8,159,276. The shares were liquidated at prices fluctuating between $53.39 and $54.94 per share. These sales were facilitated through a pre-arranged 10b5-1 trading plan that Mr. Hite established on March 20, 2026.
The execution of these sales coincides with Royalty Pharma shares trading close to their 52-week high of $56.50. The company's stock has delivered a substantial 54% return over the previous year. Valuation analysis from InvestingPro suggests the stock may be trading at a premium relative to its estimated Fair Value. Detailed valuation metrics and exclusive insights regarding RPRX and over 1,400 other US equities are accessible through InvestingPro’s comprehensive Pro Research Report.
The divestment activity was structured across two distinct transactions, both utilizing shares held indirectly via SCH Investment Partners LLC. The initial transaction saw the disposal of 32,408 shares at a weighted average price of $54.107. These shares were sold in multiple increments at prices ranging from $53.39 to $54.38. The subsequent transaction involved the sale of 117,592 shares at a weighted average price of $54.4746, with individual sales occurring between $54.39 and $54.94.
Following these transactions, Mr. Hite’s indirect holdings through SCH Investment Partners LLC stand at 559,399 Class A Ordinary Shares. He also maintains a direct holding of 70,000 Class A Ordinary Shares. Furthermore, family vehicles controlled by Mr. Hite hold limited partnership interests in RPI US Partners 2019, LP, which are exchangeable into 866,410 Class A Ordinary Shares. These vehicles also hold Class E Ordinary Shares of Royalty Pharma Holdings Ltd, exchangeable into 1,238,789 Class A Ordinary Shares, subject to specific vesting conditions.
Recent corporate developments highlight Royalty Pharma's robust financial performance for the first quarter of 2026. The company reported double-digit growth in both portfolio receipts and royalty receipts. While specific earnings per share and revenue forecasts were not disclosed, the performance indicates strong business momentum. The company’s diversified portfolio and strategic investments are cited as key drivers of its growth prospects. The positive financial results reflect strong investor sentiment towards Royalty Pharma. Analyst firms have not provided any recent upgrades or downgrades regarding the company’s stock. These developments underscore the company’s confidence in its long-term growth strategy.
The financial landscape for Royalty Pharma continues to be monitored closely by investors. The company's stock price is currently recorded at $54.69, reflecting a +0.41 increase or 0.76% gain. The closing price was noted at 15:59:59 in USD. After hours trading at 16:55:07 showed no change. The stock's performance is tracked across various timeframes including 1D, 1W, 1M, 6M, 1Y, 5Y, and Max. The company is included in AI-picked strategies, and investors are encouraged to review these strategies. The Fastest Way to determine if RPRX is a bargain involves using a Fair Value calculator. This tool utilizes a mix of 17 proven industry valuation models for maximum accuracy. Investors can obtain the bottom line for RPRX plus thousands of other stocks to find hidden gems with massive upside. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.